Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC3 | O15438 | 1/20 | 0.42 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.42 |
| ▸ | HMGCR | P04035 | 3/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | PDE6D | O43924 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1739610 | 0.99 | ABCC3 (0.43) | ABCC3ABCC4HMGCRHDAC1HDAC2 | |
| SCHEMBL2684321 | 0.98 | ABCC3 (0.42) | ABCC3ABCC4HMGCRHDAC1HDAC2 | |
| Tert-Butylamine SCHEMBL1739620 | 0.92 | HMGCR (0.40) | ABCC3ABCC4HMGCRHDAC1HDAC2 | |
| SCHEMBL1740055 | 0.91 | HMGCR (0.41) | ABCC3ABCC4HMGCRHDAC1HDAC2 | |
| SCHEMBL3971715 | 0.88 | ABCC3 (0.38) | ABCC3ABCC4HMGCRHDAC1HDAC2 | |
| Zinc Ion SCHEMBL1078270 | 0.82 | ABCC3 (0.45) | ABCC3ABCC4HMGCRHDAC1HDAC2 | |
| SCHEMBL4150176 | 0.82 | ABCC3 (0.62) | ABCC3ABCC4HMGCRHDAC1HDAC2 | |
| SCHEMBL19474869 | 0.82 | ABCC3 (0.62) | ABCC3ABCC4HMGCRHDAC1HDAC2 | |
| Zinc Ion SCHEMBL3884322 | 0.82 | ABCC3 (0.60) | ABCC3ABCC4HMGCRHDAC1HDAC2 | |
| SCHEMBL4538040 | 0.81 | ABCC3 (0.62) | ABCC3ABCC4HMGCRHDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2662478-B1 | ALUMINIUM OR ALUMINIUM ALLOY MOLTEN SALT ELECTROPLATING BATH HAVING GOOD THROWING POWER, AND ELECTROPLATING METHOD AND PRETREATMENT METHOD USING SAME | DIPSOL CHEM (JP) | 2019-08-14 | — | — | EP | claimed |
| US-10309025-B2 | Aluminum or aluminum alloy molten salt electroplating bath having good throwing power, electroplating method using the bath, and pretreatment method of the bath | DIPSOL CHEMICALS CO., LTD. (JP) | 2019-06-04 | — | — | US | claimed |
| US-20180163316-A1 | ALUMINUM OR ALUMINUM ALLOY MOLTEN SALT ELECTROPLATING BATH HAVING GOOD THROWING POWER, ELECTROPLATING METHOD USING THE BATH, AND PRETREATMENT METHOD OF THE BATH | DIPSOL CHEMICALS CO., LTD. (JP) | 2018-06-14 | — | — | US | claimed |
| US-9926638-B2 | Aluminum or aluminum alloy molten salt electroplating bath having good throwing power, electroplating method using the bath, and pretreatment method of the bath | DIPSOL CHEMICALS CO., LTD. (JP) | 2018-03-27 | — | — | US | claimed |
| EP-2662478-A1 | ELECTRICAL ALUMINIUM OR ALUMINIUM ALLOY FUSED SALT PLATING BATH HAVING GOOD THROWING POWER, AND ELECTROPLATING METHOD AND PRETREATMENT METHOD USING SAME | Dipsol Chemicals Co., Ltd. (JP) | 2013-11-13 | — | — | EP | claimed |
| US-20130292255-A1 | ALUMINUM OR ALUMINUM ALLOY MOLTEN SALT ELECTROPLATING BATH HAVING GOOD THROWING POWER, ELECTROPLATING METHOD USING THE BATH, AND PRETREATMENT METHOD OF THE BATH | DIPSOL CHEMICALS CO., LTD (JP) | 2013-11-07 | — | — | US | claimed |
| EP-2483248-B1 | CRYSTALLINE FORM I ROSUVASTATIN ZINC SALT | EGIS GYÓGYSZERGYÁR ZRT (HU) | 2016-07-20 | — | — | EP | disclosed |
| US-9321733-B2 | Crystalline pharmaceutically active ingredients | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2016-04-26 | — | — | US | disclosed |
| US-9023838-B2 | Crystalline form I rosuvastatin zinc salt | EGIS GYOGYSZERGYAR NYILVANOSAN MUEKOEDOE (HU) | 2015-05-05 | — | — | US | disclosed |
| US-20130296353-A1 | CRYSTALLINE PHARMACEUTICALLY ACTIVE INGREDIENTS | EGIS Gyogyszergyar Nyilvanosan Mukodo Reszvenytar- sasag (HU) | 2013-11-07 | — | — | US | disclosed |
| EP-2640710-A2 | CRYSTALLINE PHARMACEUTICALLY ACTIVE INGREDIENTS | Egis Gyógyszergyár Nyilvánosan Müködö Részvénytársaság (HU) | 2013-09-25 | — | — | EP | disclosed |
| US-8507513-B2 | Process for the preparation of rosuvastatin salts | EGIS GYOGYSZERGYAR NYILVANOSAN MUEKOEDOE RESZVENYTARSASAG (HU) | 2013-08-13 | — | — | US | disclosed |
| US-20120178729-A1 | CRYSTALLINE FORM I ROSUVASTATIN ZINC SALT | EGIS GYOGYSZERGYAR NYILVANOSAN MUEKOEDOE (HU) | 2012-07-12 | — | — | US | disclosed |
| WO-2012066365-A2 | CRYSTALLINE PHARMACEUTICALLY ACTIVE INGREDIENTS | EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság (HU) | 2012-05-24 | — | — | WO | disclosed |
| US-20120116082-A1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN SALTS | EGIS GYOGYSZERGYAR NYILVANOSAN MUEKOEDOE RESZVENYTARSASAG (HU) | 2012-05-10 | — | — | US | disclosed |
| EP-2389365-A1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN SALTS | Egis Gyógyszergyár Nyilvánosan Müködö (HU) | 2011-11-30 | — | — | EP | disclosed |
| US-8040819-B2 | Discovery and identification of upstream device characteristics for self-configuration of customer premises equipment | CISCO TECHNOLOGY, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| WO-2010082072-A1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN SALTS | EGIS GYÓGYSZERGYÁR (HU) | 2010-07-22 | — | — | WO | disclosed |
| WO-2009047577-A1 | PROCESS FOR PREPARATION OF ROSUVASTATIN ZINC SALT | EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság (HU) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116082-A1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN SALTS | TERT, SLC30A6, HMGCR | ABCC3 3386/4885ABCC4 3596/4885HMGCR 3/4885 |
| US-20120178729-A1 | CRYSTALLINE FORM I ROSUVASTATIN ZINC SALT | SLC39A11, PCSK9, SLC39A3 | ABCC3 1152/4885ABCC4 889/4885HMGCR 7/4885 |
| US-20130296353-A1 | CRYSTALLINE PHARMACEUTICALLY ACTIVE INGREDIENTS | PCSK9, SLC39A11, SLC10A1 | ABCC3 620/4885ABCC4 488/4885HMGCR 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.